EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 264 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line... May 22, 2023 Woman with Strong Family History of Cancer Finally Gets Diagnosis After... November 4, 2020 A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically... April 30, 2025 A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with... January 16, 2026 Load more HOT NEWS Opinion: ‘Wales needs more than a three-page statement to get cancer... Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group... For Women With Dense Breasts, An MRI May Be A Better... News digest – targeted drug approval, microbubble ‘warheads’ and prostate cancer...
